KESTRA MEDICAL TECHNOLOGIES, LTD.
Financial highlights
| Metric | FY 04/30/25 | FY 04/30/24 | FY 04/30/23 |
|---|---|---|---|
| Income Statement | |||
| Revenue | $59.8M | $27.8M | — |
| Cost of revenue | $35.6M | $27.5M | — |
| Gross profit | $24.2M | $362,000 | — |
| Selling, general & administrative | $114.9M | $69.9M | — |
| Research and development | $15.7M | $15.5M | — |
| Operating expenses | $130.6M | $85.4M | — |
| Operating income | -$106.4M | -$85.1M | — |
| Interest expense | $7.7M | $6.2M | — |
| Pretax income | -$113.7M | -$94.1M | — |
| Income tax expense | $135,000 | $24,000 | — |
| Net income | -$113.8M | -$94.1M | — |
| Balance Sheet | |||
| Cash and equivalents | $237.6M | $8.2M | — |
| Current assets | $255.3M | $14.9M | — |
| Total assets | $295.7M | $45.9M | — |
| Current liabilities | $38.0M | $33.0M | — |
| Total liabilities | $90.3M | $78.2M | — |
| Total debt | $41.1M | $42.5M | — |
| Stockholders' equity | $205.4M | -$209.4M | -$117.6M |
| Cash Flow Statement | |||
| Cash from operations | -$77.6M | -$72.2M | — |
| Depreciation and amortization | $8.0M | $11.6M | — |
| Stock-based compensation | $24.3M | $1.5M | — |
| Capital expenditure | $22.9M | $12.2M | — |
| Free cash flow | -$100.5M | -$84.5M | — |
Shares outstanding 58.4M · Free float 7.4%
Annual filing data through FY ended April 30, 2025; float as of July 16, 2026.